News in HIV infection, long-acting injectable treatments

Long-acting injectable therapies have been added to the pharmacological arsenal available for the management of HIV infection, whether in the form of monotherapy (injectable cabotegravir) as part of pre-exposure prophylaxis (PrEP) or dual therapies (injectable cabotegravir/rilpivirine) for the treat...

Full description

Saved in:
Bibliographic Details
Published inRevue médicale suisse Vol. 19; no. 812; p. 243
Main Authors Nawej Tshikung, Olivier, Segeral, Olivier, Cavassini, Matthias, Calmy, Alexandra
Format Journal Article
LanguageFrench
Published Switzerland 01.02.2023
Subjects
Anti-HIV Agents
Anti-Retroviral Agents - therapeutic use
HIV Infections - drug therapy
HIV Infections - prevention & control
Humans
Pre-Exposure Prophylaxis - methods
Pyridones - therapeutic use
Online AccessGet full text

Cover

More Information
Summary:Long-acting injectable therapies have been added to the pharmacological arsenal available for the management of HIV infection, whether in the form of monotherapy (injectable cabotegravir) as part of pre-exposure prophylaxis (PrEP) or dual therapies (injectable cabotegravir/rilpivirine) for the treatment of HIV. These treatments are the subject of new international recommendations following the publication of pivotal trials, the results of which will be presented in this review. We will also discuss the practical modalities of their implementation as well as the challenges to be faced in the future.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Review-1
ObjectType-Article-3
ISSN:1660-9379
DOI:10.53738/REVMED.2023.19.812.243